Although the MS group had significantly greater levels of serum and CSF IGFBP7 than the NMOSD group in both the study cohort and validation cohort, IGFBP7 had an exceedingly low AUC and poor specificity (0%) when differentiating NMOSD from MS. The gene discussed is IGFBP7; the disease is myeloid sarcoma.